Pfizer sales rose 31% to $17.7 billion in the third quarter of 2024, driven by a surge in demand for the pharma giant’s COVID-19 medications. AbbVie announced Monday that it is buying Aliada ...

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax ...

The team includes Bob Whitehead (Executive Chairman), a veteran in the bioscience field known for successful strategic exits and initiatives; Ramakrishna Venugopalan, PhD (Co-Founder & CEO), a former ...

On 14 November, Eli Lilly became a part of this group, after an account using its name and logo ... pharma companies, HCPs, and patients that rely on the platform for communication. Pharma giant ...

On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Brian Skorney has given his Buy rating due to a combination of factors including the recent failure of AbbVie’s emraclidine in Phase ... Inc. operates as a product based bio-pharmaceutical company. It ...

Rhineland-Palatinate, speaks at the official ground-breaking ceremony for the construction of a new research and development building on the premises of the pharmaceutical company AbbVie.

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...

A splashy recent acquisition by the company might not be panning out. Just before the market open on Monday, AbbVie revealed that its emraclidine schizophrenia treatment did not meet its primary ...